Life Sciences Archives - Page 13 of 21 - Becker's Hospital Review

J&J to resolve most cancer talc claims for $6.5B | Walmart Health shutters | FDA approves Pfizer's 1st gene therapy | 25 most expensive hospital drugs | 11 drugs in shortage

May 1, 2024 BHR Newsletter 1. J&J to resolve most cancer talc claims for $6.5B Full story 2. Walmart Health to close all 51 health clinics, virtual care Full story 3. 11 drugs now in shortage Full story 4. Thousands…

25 most popular drugs | Hospitals slam FTC's noncompete ban | Lawmakers probe Novo Nordisk | Eli Lilly scoops injectable manufacturing site from Nexus | 4 Ozempic updates

April 24, 2024 BHR Newsletter 1. 25 most popular drugs in healthcare Full story 2. Hospitals slam FTC's noncompete ban Full story 3. 4 Ozempic updates Full story 4. Cyberattacks are swelling. Deflate risk and protect your patients with an…

Drug shortages hit 23-year high | Pfizer to lay off 119 | Biotech CEO sentenced for $28M fraud scheme | HCA, CHS, Tenet and UHS exec pay

April 17, 2024 BHR Newsletter 1. Biotech CEO sentenced for $28M fraud scheme Full story 2. Executive compensation at HCA, CHS, Tenet and UHS: 7 things to know Full story 3. Pfizer to lay off 119, wind down plant's construction…

Drugmaker files for bankruptcy | A potential Ozempic baby boom | 2nd ransomware group targets Change | Zepbound now in shortage | Amylyx to pull ALS therapy from market

April 10, 2024 BHR Newsletter 1. New York drugmaker files for bankruptcy Full story 2. 2nd ransomware group reportedly tries to extort Change Healthcare Full story 3. A possible Ozempic baby boom Full story 4. Take manual tasks off your…

The $5 Ozempic debate | 3 drugmakers announce recalls | 10 drugs now in shortage | 35 billionaires in US healthcare | Verily cuts jobs

April 3, 2024 BHR Newsletter 1. 3 drugmakers announce recalls Full story 2. 35 billionaires in US healthcare Full story 3. 10 drugs now in shortage Full story 4. Less is more' is the ethos driving innovative hospitals' digital experiences…

The $4.25M drug | Wegovy sidesteps 'forever drug' problem | A new COVID-19 drug | Novo Nordisk to buy drugmaker for $1.1B | FDA rejects cancer drug candidate

March 27, 2024 BHR Newsletter 1. Wegovy sidesteps the 'forever drug' problem Full story 2. Beth Israel violated 'cease and desist' order, state alleges Full story 3. The new COVID-19 drug: 4 notes Full story 4. You lose patients (and…

GSK, Duke halt RSV shot trial | Eli Lilly, Amazon partner on weight loss drug delivery | AstraZeneca to acquire Fusion Pharmaceuticals in $2.4B deal | 9 drugs now in shortage

Becker's Life Sciences is a top resource for healthcare leaders and one of our most-read newsletters. If this is in your “promotions” folder, please drag it to your regular inbox so you can receive future updates. March 20, 2024 BHR Newsletter…

FDA delays decision on Eli Lilly Alzheimer's drug | Amylyx may pull ALS drug | Syphilis drug shortage may end in Q4 | Wegovy secures 2nd indication | 9 Ozempic updates

Becker's Life Sciences is a top resource for healthcare leaders and one of our most-read newsletters. If this is in your “promotions” folder, please drag it to your regular inbox so you can receive future updates. March 13, 2024 BHR Newsletter…

Mark Cuban dives into drug manufacturing | Drugmakers send CMS counteroffers in fair price negotiations | 8 Ozempic updates | 1st OTC glucose monitor cleared | FDA revokes approval of Pepaxto

March 6, 2024 BHR Newsletter 1. Mark Cuban's pharma company to start manufacturing 2 drugs this week Full story 2. HHS intervenes in Change Healthcare hack Full story 3. 8 Ozempic updates Full story 4. Behind a big chunk of…

Weight loss drug candidate could rival Ozempic | State board sets a drug price ceiling | NY asks FDA to address Singulair controversy | Amgen builds $474M facility | 2 drugs nearing approval to know

February 28, 2024 BHR Newsletter 1. A weight loss drug candidate could rival Ozempic Full story 2. Justice Department begins antitrust investigation into UnitedHealth Full story 3. For 1st time, state board sets a drug price ceiling Full story 4.…